Home -> Law Blog Directory -> Intellectual Property Law Blogs -> IPKat
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: IPKatPharma patents and Article 31bis: where are we now?
By Johanna Gibson, David Pearce, Jeremy Phillips and Ilanah Simon.
ADVERTISEMENTS
With so many major changes and developments occurring on his very doorstep, the IPKat has rather taken his eye off activities at global level. For example, in August 2003, when this blog was just 10 weeks old, the World Trade Organization (WTO) passed a decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. This decision called for the establishment of a dedicated page on the WTO website, to make publicly available certain notifications relating to the manufacture and sale of patented drugs for the benefit of some of the world's poorest countries. In December 2005 this decision was replaced by a fresh one, which would amend TRIPS itself once accepted by two thirds of the TRIPS membership, enacting a new Article 31bis that would formally legitimise the Doha principle while retaining the notification system.
The IPKat recalls that European Union law is itself Doha-compliant. He also understands that the deadline for getting the two-thirds signed up is 31 December 2009, which is only a few short months away. What's the current state of play, he wonders? Can any reader advise?
Full post as published by IPKat on August 16, 2009 (boomark / email).
Lawsuits and Settlements
Medical Records
To Stay out of Pharma's Hands
Hormone Replacement Therapy Lawsuits See Multi-Million Dollar Settlements
HRT Lawsuits Pharma Faces Multi Million Dollar Settlements
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

New L&C Law Scholarship: Pharmas Nonobvious Problem
Pharma Prosecution: CIP Breaks Priority for Restricted Claims
Biotech Patents: Strategies for an Evolving Legal Climate
Updated: List of Pharma-Free Experts Published
More § 154(b)(4)(A) Actions Filed against Director








